Head-to-head · checked 2026-08-07
Retatrutide vs Wegovy: triple agonist vs the most studied GLP-1 on the market
Wegovy (semaglutide) is the single most researched weight-loss injection in the UK, with cardiovascular outcomes data no other drug in this comparison can match. Retatrutide's trial numbers are bigger — but "bigger number" and "more established" are different kinds of evidence.
| Wegovy (semaglutide) | Retatrutide | |
|---|---|---|
| Receptors targeted | GLP-1 only | GLP-1 + GIP + glucagon |
| Best reported weight loss | ~15% (STEP trials) | Up to 30.3% (TRIUMPH-1, phase 3) |
| Cardiovascular outcomes evidence | SELECT trial: 20% reduction in major cardiac events — a dedicated, completed outcomes trial | Risk markers improved in TRIUMPH-3; no dedicated long-term outcomes trial yet |
| UK status | Licensed & available | Not licensed anywhere — phase 3 only |
| Manufacturer | Novo Nordisk | Eli Lilly |
Bigger trial numbers vs a longer track record
These are genuinely different strengths, not the same evidence at different sizes.
Where Wegovy is ahead
Semaglutide has years of real-world prescribing behind it and the SELECT trial — a dedicated cardiovascular outcomes study most weight-loss drugs, including retatrutide so far, don't have.
Where retatrutide's trial data is ahead
Adding the glucagon receptor on top of GLP-1 produced roughly double Wegovy's weight-loss result in TRIUMPH-1 — but that's phase 3 trial data, not years of monitored real-world use.
The practical takeaway today
Wegovy is licensed, available through regulated UK pharmacies, and backed by the deepest safety record of any drug in this comparison. Retatrutide's higher trial percentage doesn't change that there's no legal way to access it in the UK yet — realistic licensing is 2027–2028.
Retatrutide UK statusFull evidence & regulatory record
Compare Wegovy providersWegoCompare →
Wegovy pill optionCompareWegovyPrices →